<?xml version='1.0' encoding='utf-8'?>
<document id="25473292"><sentence text="Macitentan for the treatment of pulmonary arterial hypertension."><entity charOffset="0-10" id="DDI-PubMed.25473292.s1.e0" text="Macitentan" /></sentence><sentence text="Macitentan is the most recently approved dual endothelin-receptor antagonist (ERA) for the treatment of symptomatic pulmonary arterial hypertension"><entity charOffset="0-10" id="DDI-PubMed.25473292.s2.e0" text="Macitentan" /></sentence><sentence text=" Compared to other available ERAs, it demonstrates superior receptor-binding properties, with consequently improved tissue penetration, and a longer duration of action allowing for once-daily dosing" /><sentence text=" It has a favorable adverse-effect profile, with notably no demonstrable increase in the risk of hepatotoxicity or peripheral edema, but like other ERAs, it is potentially limited by significant anemia" /><sentence text=" Phase I data have demonstrated a favorable drug-drug interaction profile and no need for dose adjustment with hepatic and renal impairment" /><sentence text=" In the pivotal SERAPHIN study, treatment of symptomatic pulmonary arterial hypertension patients with macitentan led to statistically significant improvements in functional class, exercise tolerance, and hemodynamic parameters, in addition to a reduction in morbidity in an event-driven long-term trial"><entity charOffset="103-113" id="DDI-PubMed.25473292.s6.e0" text="macitentan" /></sentence><sentence text=" " /></document>